The importance of individually customized treatment for CLL patients
Cytokine release syndrome: a limiting factor for AML treatment
Current investigations in the use of allogeneic transplant in the treatment of myeloma
Bispecific agents: the future of AML and MDS treatment?
Long-term follow-up: AML17 trial of ATO and ATRA vs the standard of care in APL
Alan K. Burnett